A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania

Journal of Clinical Psychiatry

Volumn 71, Issue 10, 2010, Pages 1336-1343

  Van Ameringen, Michael ^a,b   Mancini, Catherine ^a,b   Patterson, Beth ^b   Bennett, Mark ^b   Oakman, Jonathan ^c  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^c UNIVERSITY OF WATERLOO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

OLANZAPINE; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; MALE; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT OUTCOME; TRICHOTILLOMANIA; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; TRICHOTILLOMANIA;

EID: 78149297101     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.09m05114gre     Document Type: Article

References (60)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
2. O'Sullivan RL, Mansueto CS, Lerner EA, et al. Characterization of trichotillomania: a phenomenological model with clinical relevance to obsessive-compulsive spectrum disorders. Psychiatr Clin North Am. 2000;23(3):587-604. doi:10.1016/S0193-953X(05)70182-9 PubMed
3. Chamberlain SR, Menzies L, Sahakian BJ, et al. Lifting the veil on trichotillomania. Am J Psychiatry. 2007;164(4):568-574. doi:10.176/api.ajp.164. 4.568 PubMed
4. Mansueto CS, Stemberger RM, Thomas AM, et al. Trichotillomania: a comprehensive behavioral model. Clin Psychol Rev. 1997;17(5):567-577. doi:10.1016/S0272-7358(97)028-7 PubMed
5. Swedo SE, Lenane MC, Leonard HL. Long-term treatment of trichotillomania (hair pulling). N Engl J Med. 1993;329(2):141-142. doi:10.1056/NEJM1930708329020 PubMed
6. Swedo SE, Leonard HL, Rapoport JL, et al. A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). N Engl J Med. 1989;321(8):497-501. PubMed
7. Ninan PT, Knight B, Kirk L, et al. A controlled trial of venlafaxine in trichotillomania: interim phase I results. Psychopharmacol Bull. 1998;34(2):221-224. PubMed
8. Stein DJ, Mullen L, Islam MN, et al. Compulsive and impulsive symptomatology in trichotillomania. Psychopathology. 1995;28(4):208-213. PubMed
9. Hollander E, Benzaquen SD. The obsessive-compulsive spectrum disorders. Int Rev Psychiatry. 1997;9(1):99-110. doi:10.1080/0954026975628
10. Bienvenu OJ, Samuels JF, Riddle MA, et al. The relationship of obsessive-compulsive disorder to possible spectrum disorders: results from a family study. Biol Psychiatry. 2000;48(4):287-293. doi:10.1016/S06-323(0)0831-3 PubMed
11. Stein DJ, Bouwer C, Niehaus DJ. Stereotypic movement disorder. J Clin Psychiatry. 1997;58(4):177-178. PubMed
12. Stein DJ, Lochner C. Obsessive-compulsive spectrum disorders: a multidimensional approach. Psychiatr Clin North Am. 2006;29(2):343-351. doi:10.1016/j.psc.206.02.015 PubMed
13. Tükel R, Keser V, Karali NT, et al. Comparison of clinical characteristics in trichotillomania and obsessive-compulsive disorder. J Anxiety Disord. 2001;15(5):433-441. doi:10.1016/S087-6185(01)074-3 PubMed
14. Lochner C, Hemmings SMJ, Kinnear CJ, et al. Cluster analysis of obsessive-compulsive spectrum disorders in patients with obsessive-compulsive disorder: clinical and genetic correlates. Compr Psychiatry. 2005;46(1):14-19. doi:10.1016/j.compsych.204.07.020 PubMed
15. Stein DJ, Hollander E. Low-dose pimozide augmentation of serotonin reuptake blockers in the treatment of trichotillomania. J Clin Psychiatry. 1992;53(4):123-126. PubMed
16. Lochner C, Stein DJ. Does work on obsessive-compulsive spectrum disorders contribute to understanding the heterogeneity of obsessive-compulsive disorder? Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(3):353-361. doi:10.1016/j.pnpbp.205.1.04 PubMed
17. Goodman WK, McDougle CJ, Price LH, et al. Beyond the serotonin hypothesis: a role for dopamine in some forms of obsessive compulsive disorder? J Clin Psychiatry. 1990;51(suppl):36-43, discussion 55-58. PubMed
18. Shapiro AK, Shapiro E. Evaluation of the reported association of obsessive-compulsive symptoms or disorder with Tourette's disorder. Compr Psychiatry. 1992;33(3):152-165. doi:10.1016/010-40X(92)9024-K PubMed
19. O'Sullivan RL, Rauch SL, Breiter HC, et al. Reduced basal ganglia volumes in trichotillomania measured via morphometric magnetic resonance imaging. Biol Psychiatry. 1997;42(1):39-45. doi:10.1016/S06-323(96)0297-1 PubMed
20. Keuthen NJ, Makris N, Schlerf JE, et al. Evidence for reduced cerebellar volumes in trichotillomania. Biol Psychiatry. 2007;61(3):374-381. doi:10.1016/j.biopsych.206.06.013 PubMed
21. Rauch SL, Wright CI, Savage CR, et al. Brain activation during implicit sequence learning in individuals with trichotillomania. Psychiatry Res. 2007;154(3):233-240. doi:10.1016/j.pscychresns.206.09.02 PubMed
22. Saxena S. Neuroimaging in obsessive-compulsive related disorders. Presented at the 160th annual meeting of the American Psychiatric Association; May 22, 2007; San Deigo, CA.
23. Swedo SE, Rapoport JL, Leonard HL, et al. Regional cerebral glucose metabolism of women with trichotillomania. Arch Gen Psychiatry. 1991;48(9):828-833. PubMed
24. Stein DJ, van Heerden B, Hugo C, et al. Functional brain imaging and pharmacotherapy in trichotillomania. Single photon emission computed tomography before and after treatment with the selective serotonin reuptake inhibitor citalopram. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26(5):885-890. doi:10.1016/S0278-5846(01)034-7 PubMed
25. Stanley MA, Breckenridge JK, Swann AC, et al. Fluvoxamine treatment of trichotillomania. J Clin Psychopharmacol. 1997;17(4):278-283. doi:10.1097/04714-197080-07 PubMed
26. Koran LM, Ringold A, Hewlett W. Fluoxetine for trichotillomania: an open clinical trial. Psychopharmacol Bull. 1992;28(2):145-149. PubMed
27. Lochner C, Seedat S, Niehaus DJH, et al. Topiramate in the treatment of trichotillomania: an open-label pilot study. Int Clin Psychopharmacol. 2006;21(5):255-259. doi:10.1097/04850-206090-02 PubMed
28. Christenson GA, Mackenzie TB, Mitchell JE, et al. A placebo-controlled, double-blind crossover study of fluoxetine in trichotillomania. Am J Psychiatry. 1991;148(11):1566-1571. PubMed
29. Streichenwein SM, Thornby JI. A long-term, double-blind, placebo- controlled crossover trial of the efficacy of fluoxetine for trichotillomania. Am J Psychiatry. 1995;152(8):1192-1196. PubMed
30. Pigott TA, L'Heureux F, Hill JL, et al. A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive- compulsive disorder. J Clin Psychopharmacol. 1992;12(1):11-18. PubMed doi:10.1097/04714-192020-03
31. Dougherty DD, Loh R, Jenike MA, et al. Single modality versus dual modality treatment for trichotillomania: sertraline, behavioral therapy, or both? J Clin Psychiatry. 2006;67(7):1086-1092. doi:10.408/JCP.v67n071 PubMed
32. Christenson GA, Crow SJ, Mackenzie TB, et al. A placebo controlled double-blind study of naltrexone for trichotillomania. In: New Research Program and Abstracts of the 147th Annual Meeting of the American Psychiatric Association; May 21-26, 1994; Philadelphia, PA. Abstract NR597:212.
33. Van Ameringen M, Mancini C, Oakman JM, et al. The potential role of haloperidol in the treatment of trichotillomania. J Affect Disord. 1999;56(2-3):219-226. doi:10.1016/S0165-0327(9)019-1 PubMed
34. Stewart RS, Nejtek VA. An open-label, flexible-dose study of olanzapine in the treatment of trichotillomania. J Clin Psychiatry. 2003;64(1):49-52. PubMed
35. O'Sullivan RL, Keuthen NJ, Hayday CF, et al. The Massachusetts General Hospital (MGH) Hairpulling Scale: 2. reliability and validity. Psychother Psychosom. 1995;64(3-4):146-148. PubMed
36. Keuthen NJ, O'Sullivan RL, Ricciardi JN, et al. The Massachusetts General Hospital (MGH) Hairpulling Scale: 1. development and factor analyses. Psychother Psychosom. 1995;64(3-4):141-145. doi:10.159/028903 PubMed
37. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health; 1976:218-222.
38. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV). Washington, DC: American Psychiatric Press; 1996.
39. Christenson GA, Mackenzie TB, Mitchell JE. Characteristics of 60 adult chronic hair pullers. Am J Psychiatry. 1991;148(3):365-370. PubMed
40. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale, 1: development, use, and reliability. Arch Gen Psychiatry. 1989;46(11):1006-1011. PubMed
41. Endicott J, Nee J, Harrison W, et al. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull. 1993;29(2):321-326. PubMed
42. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561-571. PubMed
43. Beck AT, Epstein N, Brown G, et al. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988;56(6):893-897. doi:10.1037/02-06X.56.6.893 PubMed
44. Sheehan DV. The Anxiety Disease. New York, NY: Bantam Books; 1983.
45. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;45(suppl 212):11-19. doi:10.1/j.160-047.1970. tb0206.x
46. Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154(5):672-676. doi:10.192/bjp.154.5.672 PubMed
47. Psychopharmacology Research Branch, National Institute of Mental Health. Abnormal Involuntary Movement Scale (AIMS). In: Guy W, ed. ECDEU Assessment Manual for Psychopharmacology, Revised. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health; 1976:534-537.
48. Duggan L, Fenton M, Rathbone J, et al. Olanzapine for schizophrenia. Cochrane Database Syst Rev. 2005;2:1-384. PubMed
49. Cipriani A, Rendell JM, Geddes J. Olanzapine in long-term treatment for bipolar disorder. Cochrane Database Syst Rev. 2009;1:1-98. PubMed
50. Rendell JM, Gijsman HJ, Keck P, et al. Olanzapine alone or in combination for acute mania. Cochrane Database Syst Rev. 2003;3:1-160. PubMed
51. Lipkovich I, Baron D, Houston J, et al. Flexible-dose clinical trials: predictors and outcomes of antipsychotic dose adjustments. J Clin Psychopharmacol. 2005;25(4):381-386. doi:10.1097/01.jcp.016791.7064.d4 PubMed
52. Koller EA, Doraiswamy PM. Olanzapine-associated diabetes mellitus. Pharmacotherapy. 2002;22(7):841-852. doi:10.1592/phco.2.1.841.3629 PubMed
53. Parsons B, Allison DB, Loebel A, et al. Weight effects associated with antipsychotics: a comprehensive database analysis. Schizophr Res. 2009;110(1-3):103-110. doi:10.1016/j.schres.208.09.025 PubMed
54. Rapaport MH, Frevert T, Babior S, et al. Comparison of descriptive variables for symptomatic volunteers and clinical patients with anxiety disorders. Anxiety. 1996;2(3):117-122. doi:10.102/(SICI)152-7154(196)2: 3〈17:AID-ANXI2〉3.0.CO;2-M PubMed (Pubitemid 126812817)
55. Azorin JM, Kaladjian A. An update on the treatment of bipolar depression. Expert Opin Pharmacother. 2009;10(2):161-172. doi:10.1517/14656560802653172 PubMed
56. Trivedi MH, Thase ME, Osuntokun O, et al. An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatmentresistant depression. J Clin Psychiatry. 2009;70(3):387-396. doi:10.408/JCP.08m04064 PubMed
57. Choi JS, Kim SH, Yoo SY, et al. Shape deformity of the corpus striatum in obsessive-compulsive disorder. Psychiatry Res. 2007;155(3):257-264. doi:10.1016/j.pscychresns.207.02.04 PubMed
58. Kang DH, Kim JJ, Choi JS, et al. Volumetric investigation of the frontal-subcortical circuitry in patients with obsessive-compulsive disorder. J Neuropsychiatry Clin Neurosci. 2004;16(3):342-349. PubMed
59. Rauch SL, Jenike MA, Alpert NM, et al. Regional cerebral blood flow measured during symptom provocation in obsessive-compulsive disorder using oxygen 15-labeled carbon dioxide and positron emission tomography. Arch Gen Psychiatry. 1994;51(1):62-70. PubMed
60. Bohlhalter S, Goldfine A, Matteson S, et al. Neural correlates of tic generation in Tourette syndrome: an event-related functional MRI study. Brain. 2006;129(8):2029-2037. doi:10.1093/brain/awl050 PubMed